Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Oruka ...

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

Stifel has launched its coverage on pre-clinical stage biotech Oruka Therapeutics (NASDAQ:ORKA) with a buy recommendation and a $49 price target, citing its lead candidates ORKA-001 and ORKA-002 ...

Board members include Lawrence Klein, Ph.D., CEO of Oruka Therapeutics; Erin Lavelle, former Chief Operating Officer and Chief Financial Officer at ProfoundBio and Eliem Therapeutics; Chris Cain ...

Dai Nippon Printing Co., Ltd. +7.53% +34.58% Dai Nippon Printing Co., Ltd. +0.00% +0.00% ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases ...